Keeping Track: Quick Trips From Breakthrough Designation To Market

 
• By Bridget Silverman

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Keeping Track Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers